Shanghai Xiao Fang PharmaceuticalLtd Valuation

Is 603207 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 603207 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 603207 (CN¥25.3) is trading below our estimate of fair value (CN¥33.42)

Significantly Below Fair Value: 603207 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 603207?

Key metric: As 603207 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 603207. This is calculated by dividing 603207's market cap by their current earnings.
What is 603207's PE Ratio?
PE Ratio	20.6x
Earnings	CN¥196.77m
Market Cap	CN¥4.05b

603207 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	6.8x
Enterprise Value/EBITDA	14x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does 603207's PE Ratio compare to its peers?

The above table shows the PE ratio for 603207 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	36.3x
603676 Tibet Weixinkang Medicine	16.7x	n/a	CN¥4.1b
002393 Tianjin Lisheng PharmaceuticalLtd	24.2x	n/a	CN¥4.6b
002728 Teyi Pharmaceutical GroupLtd	61.5x	47.2%	CN¥4.3b
603566 Pulike Biological Engineering	42.7x	33.1%	CN¥4.3b
603207 Shanghai Xiao Fang PharmaceuticalLtd	20.6x	n/a	CN¥4.0b

Price-To-Earnings vs Peers: 603207 is good value based on its Price-To-Earnings Ratio (20.6x) compared to the peer average (36.3x).

Price to Earnings Ratio vs Industry

How does 603207's PE Ratio compare vs other companies in the CN Pharmaceuticals Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap

No more companies available in this PE range

0 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: 603207 is good value based on its Price-To-Earnings Ratio (20.6x) compared to the CN Pharmaceuticals industry average (31.1x).

Price to Earnings Ratio vs Fair Ratio

What is 603207's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

603207 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	20.6x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 603207's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

China Resources Double-Crane PharmaceuticalLtd

CN¥21.4b

China Resources Double-Crane Pharmaceutical Co.,Ltd.

600062

CN¥20.80

-3.9%

12.1%

Jiangsu Kanion PharmaceuticalLtd

CN¥8.1b

Researches and develops, produces, and sells Chinese medicines.

600557

CN¥14.29

-4.2%

-23.6%

Dong-E-E-JiaoLtd

CN¥36.4b

Research and development, production, and sale of Ejiao and a series of Chinese patent medicines, health foods, and foods.

423

CN¥56.60

-3.0%

13.2%